Page 1

May 12 , 2021 Xenetic BIOSCIENCES Xenetic Biosciences , Inc. Reports First Quarter 2021 Financial Results • Continued Execution on XcartTM Development Plan With Commencement of Exploratory Patient Biopsy Trial Expected To Position the Company To Conduct Ind - Enabling Studies in the United States • Licensing Partners Leveraging PolyXenⓇ Platform Technology Continue To Make Clinical , Regulatory and Commercial Advancement FRAMINGHAM , MA / ACCESSWIRE / May 12 , 2021 / Xenetic Biosciences , Inc. ( NASDAQ : XBIO ) ( " Xenetic " or the " Company " ) , a biopharmaceutical company focused on advancing XCART ™ , a personalized CAR T platform technology engineered to target patient- and tumor - specific neoantigens , today reported its financial results for the first quarter of 2021 and provided a corporate update . Xenetic BIOSCIENCES " During the first quarter our focus remained on advancing the development of our XCART ™ platform , which we believe has the potential to provide a personalized CAR T therapy targeting cancers with a patient - and tumor - specific approach . The commencement of our exploratory patient biopsy trial is a key component of our preclinical development strategy and an important step forward toward advancing into a Phase 1 study , " commented Jeffrey Eisenberg , Chief Executive Officer of Xenetic . XCARTTM Platform Technology Overview : Significantly differentiated , proprietary approach to personalized CART lymphoma therapy targeting tumor - specific antigens independently of CD19 or other surface antigens that are common to both normal and malignant B - cells . Lead program for Non - Hodgkin lymphoma , an area of significant unmet need , with the potential to address an initial global market opportunity of over $ 7 billion annually . " [ 1 ] Program Highlights : • Collaboration with Pharmsynthez and multiple academic institutions in Eastern Europe to optimize the overall XCART ™ workflow , including clinical manufacturing processes , and ultimately to conduct a first in human study in B - cell Non - Hodgkin lymphoma ( NHL ) patients . • Research and development collaboration with Scripps Research covering design and implementation of the preclinical development program , as well as method development activities supporting process development for clinical manufacturing .